Health / Health News

    Epstein-Barr virus protein can “switch on” risk genes for autoimmune diseases

    Infection with Epstein-Barr virus (EBV), the cause of infectious mononucleosis, has been associated with subsequent development of systemic lupus erythematosus and other chronic autoimmune illnesses, but the mechanisms behind this association have been unclear. Now, a novel computational method shows that a viral protein found in EBV-infected human cells may activate genes associated with increased risk for autoimmunity.



    An electron microscopy image showing three Epstein-Barr virions. Image credit: NIAID


    EBV infection is nearly ubiquitous in the human population worldwide. Most people acquire EBV in early childhood, experience no symptoms or only a brief, mild cold-like illness, and remain infected throughout their lives while remaining asymptomatic. When infection first occurs in adolescence or young adulthood, EBV can lead to a syndrome of infectious mononucleosis characterized by prolonged fever, sore throat, swollen lymph nodes and fatigue.

    This syndrome, also known as “mono” or the “kissing disease,” generally resolves with rest and only rarely causes serious complications.

    When EBV infects human immune cells, a protein produced by the virus — EBNA2 — recruits human proteins called transcription factors to bind to regions of both the EBV genome and the cell’s own genome. Together, EBNA2 and the human transcription factors change the expression of neighboring viral genes.

    In the current study, the researchers found that EBNA2 and its related transcription factors activate some of the human genes associated with the risk for lupus and several other autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, juvenile idiopathic arthritis and celiac disease.

    Researchers led by John B. Harley, M.D., Ph.D., director of the Center for Autoimmune Genomics and Etiology (CAGE) at Cincinnati Children’s Hospital Medical Center, developed a new computational and biochemical technique known as the Regulatory Element Locus Intersection algorithm, or RELI.

    The investigators found that EBNA2 bound to genes associated with the risk for multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, juvenile idiopathic arthritis and celiac disease.

    Because EBV is most often encountered in early childhood, avoiding infection is practically impossible. Now that we understand how EBV infection may contribute to autoimmune diseases in some people, researchers may be able to develop therapies that interrupt or reverse this process.

    Researchers note that EBV infection is not the only factor that contributes to the development of the seven autoimmune conditions discussed in the paper. Many of the regulatory genes that contribute to lupus and other autoimmune disorders did not interact with EBNA2, and some individuals with activated regulatory genes associated with disease risk do not develop disease. (National Institutes of Health)

    APRIL 19, 2018



    YOU MAY ALSO LIKE

    Biologic age, a DNA-based estimate of a person’s age, is associated with future development of breast cancer.
    Pollution is the world’s No. 1 killer, a new study says, causing more premature deaths than war, terrorism, natural disasters, cigarettes and disease.
    Researchers found that unmet sleep needs of the elderly elevate their risk of memory loss and a wide range of mental and physical disorders.
    Researchers say a widely-used antifungal drug may hold promise for treating people with cystic fibrosis, a life-threatening genetic disorder that causes serious damage to the lungs.
    U.S. federal health officials say the mysterious illness that has killed 13 people in Liberia came from a bacteria that can lead to the fatal brain disease meningitis.
    A study in mice provided direct evidence that the lung is a major site for production of platelets, a type of blood cell. The findings suggest new directions for developing treatments for people who have low levels of platelets.

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact